Meeting Starts In:


Redefine CQAs & Optimize Process Development with Fit-for-Purpose Analytics for Best-in-Class Product Quality

September 25-27 | Boston, MA

Join Your Only Industry-Led Summit Dedicated to Accelerating Viral Vector Characterization & Analytical Development for Cell, Gene & Vaccine Therapies

In 2023, industry is witnessing a renaissance in viral vector characterization. Spurred by widespread biopharma investment to engineer a new wave of novel capsids and faced with newly launched QbD frameworks by US Pharmacopeia and the FDA’s tightened guidance, increased vector complexity is creating a new era for advanced analytical technologies to ensure precision and accuracy.

In the wake of significant collaborations including Vector Bio and iBET’s for high-throughput characterization, and the likes of Vertex and BMS announcing their priority to build out their internal analytical competencies, the inaugural Viral Vector Characterization & Analytical Development Summit arrives to pave the foundation for teams to further optimize process development and accelerate vector scale-up with GMP compliance in mind.

Uniting Characterization, Analytical, Formulation, Quality, Engineering, CMC and Process leaders, this industry-led summit is your only for cross-learning opportunities across AAV’s, LV’s & RV’s and more – so you can benchmark your work against rapid-analytical method development transforming your peers’ workflows, turnaround, and consistency.

Stay ahead of the curve, and join the likes of Ultragenyx, Kite Pharma, BioMarin, Neogene Therapeutics, Pfizer and many more for a 3-day jam packed agenda, set to tackle your biggest bottlenecks in:

Viral Vector Characterization
Viral Vector Characterization
Viral Vector Characterization
Viral Vector Characterization
Viral Vector Characterization

Developing phase appropriate potency assays and packages to demonstrate specificity, sensitivity and accuracy of results to enable improved efficacy

Navigate the regulatory agencies’ expectation and define predictive CQA’s to provide sufficient data during IND for smooth approval process

Leverage analytics to enhance process development and formulation capabilities to protect final product safety

Apply advanced analytical technologies and interpret datapoints effectively to streamline development and align analytics with programs scaling up quickly

Establish novel characterization and analytical methods with rapid, precise and accurate results to deepen your understanding of your capsid biology, improve encapsulation efficiency, protect stability and minimize impurities

Your one-stop-shop to build out your analytical capabilities and characterization package, join 60+ technical leaders to gain practical takeaways improving analytical capabilities so critical to process development and ensuring quality for patients.

Companies in Our Event Series Community:

World-Class Speaker Faculty Includes:

2023 Partner

Pharmaron Logo

What to Expect...

Industry & Academic Presenters

Jam-Packed Days of Exclusive Content

Viral Vector Delivery Leader Attendees

Deep-Dive & Collaborative Workshops

Our Viral Vector Meeting Series Attendees Said:

Well organized event covering important topics for viral vector manufacturing and analytics. High-quality presentations and engaged audiences.”
Director & Head of Viral Vector, R&D,

I enjoyed the people, their expertise, and their willingness to speak about their experiences and issues facing the field..”
Senior Scientist, Viral Vector Process Development,
Bristol Myers Squibb

Good cross section of industry willing to discuss details.”
Senior Director of Process Science and Head of Vector Core, Affinia Therapeutics

Events in the Series: